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Abstract
Background: Rho-associated coiled-coil containing protein kinase (Rho-kinase/ROCK) is involved in various cellular
functions including cell proliferation, and is generally considered to be oncogenic, while some studies show that
ROCK functions as a negative regulator of cancer progression. As a result, the precise role of ROCK remains
controversial. We have previously reported that Rho-kinase/ROCK negatively regulates epidermal growth factor
(EGF)-induced cell proliferation in SW480 colon cancer cells. In the present study, we investigated the role of ROCK
in EGF receptor (EGFR) signaling in the pancreatic cancer cell lines, Panc1, KP3 and AsPc1.
Results: In these cells, Y27632, a specific ROCK inhibitor, enhanced EGF-induced BrdU incorporation. The blockade of
EGF stimulation utilizing anti-EGFR-neutralizing antibodies suppressed Panc1 cell proliferation. EGF induced RhoA
activity, as well as the phosphorylation of cofilin and myosin light chain (MLC), both targets of ROCK signaling, and
Y27632 suppressed both of these processes, indicating that the phosphorylation of cofilin and MLC by EGF occurs
through ROCK in Panc1 cells. EGF-induced phosphorylation of EGFR at tyrosine residues was augmented when the
cells were pretreated with Y27632 or were subjected to gene silencing using ROCK-siRNA. We also obtained similar
results using transforming growth factor-a. In addition, EGF-induced phosphorylation of p44/p42 mitogen-activated
protein kinase and Akt were also enhanced by Y27632 or ROCK-siRNA. Moreover, an immunofluorescence
microscope study revealed that pretreatment with Y27632 delayed EGF-induced internalization of EGFR. Taken
together, these data indicate that ROCK functions to switch off EGFR signaling by promoting the internalization of
the EGFR.
Conclusions: While EGF first stimulates the activation of the EGFR and subsequently increases cancer cell
proliferation, EGF concurrently induces the activation of ROCK, which then turns off the activated EGFR pathway via
a negative feedback system.
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Introduction
Pancreatic cancer is a common malignancy, ranking
thirteenth in incidence, and eighth as the cause of can-
cer-related death worldwide [1]. Surgical resection is the
only curable treatment at present, but only 10-15% of
patients are able to undergo surgery at the time of
diagnosis. Most pancreatic cancer has already reached
an advanced stage when the first symptoms appear.
Furthermore, it is difficult to diagnose pancreatic cancer
at an early stage, even with advanced medical imaging
techniques such as computed tomography and magnetic
resonance imaging.
The standard treatment for patients with advanced
pancreatic cancer is chemotherapy. Gemcitabine has
been the standard of treatment during the last decade,
but the median survival of patients treated with
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have failed to demonstrate any improvement in overall
survival with the addition of different drugs to gemcita-
bine [2]. Therefore, the development of new treatments
for unresectable pancreatic cancer is required.
The epidermal growth factor receptor (EGFR) is a
member of the ErbB family of receptor tyrosine kinases
[3]. Binding of ligands such as epidermal growth factor
(EGF) [4] or transforming growth factor-a (TGF-a)[ 5 ]
to the EGFR leads to receptor dimerization and autop-
hosphorylation [6]. The autophosphorylation of the
EGFR at tyrosine residues activates downstream signal-
ing, such as the Ras-Raf-MEK-p44/p42 mitogen-acti-
vated protein (MAP) kinase pathway or
phosphotidylinositol-3 kinase (PI3K)-Akt pathway, thus
resulting in the activation of cell proliferation [7]. The
contribution of the EGFR pathway to oncogenesis has
been well documented, and therapeutic exploitation of
this axis has proven to be successful for several types of
cancers, including colorectal and head and neck cancers
[8,9]. The EGFR has been reported to be overexpressed
in pancreatic cancer [10,11]. Therefore, EGFR activation
appears to have a pivotal role in the growth and pro-
gression of pancreatic cancer, and EGFR-mediated path-
ways appear to be important potential targets for new
therapies for this malignancy. The addition of EGFR-tar-
geted therapy to gemcitabine in advanced pancreatic
cancer has recently been demonstrated to provide a
small, but statistically significant, survival benefit [12].
Rho GTPases are small proteins that act as molecular
switches in a wide range of signaling pathways [13].
Three main classes of Rho GTPases, Rho, Rac and
Cdc42, are known to regulate actin cytoskeletal
dynamics [14]. Rho-associated coiled-coil containing
protein kinase (Rho-kinase/ROCK) was initially charac-
terized for its role in mediating the formation of RhoA-
induced stress fibers and focal adhesion through its
effects on the phosphorylation of the myosin light chain
[15]. ROCK also phosphorylates LIM kinases 1 and 2
(LIMKs), which phosphorylate cofilin [14]. The phos-
phorylation of cofilin by LIMKs inactivates its actin-
depolymerization activity [16]. Therefore, the phosphor-
ylation of LIMKs by ROCK inhibits cofilin-mediated
actin-filament disassembly and leads to an increase in
the number of actin filaments [14]. It has been reported
that the Rho-ROCK pathway plays an important role in
various cellular functions such as vascular smooth mus-
cle cell contraction, cell migration and cell proliferation
[17].
Itoh et al. first reported that the expression of consti-
tutively active ROCK promotes cell invasion, and that a
ROCK inhibitor, Y27632 [18], reduces tumor cell disse-
mination in vivo [19]. An elevated expression of RhoA,
as well as the Rho effector protein ROCK, are
commonly observed in human cancers and often asso-
ciated with more invasive and metastatic phenotypes
[20]. In addition, the expression of ROCK1 is almost
always found in pancreatic cancer tissues, but not in
normal pancreatic tissues [21]. On the other hand, a
recent report showed that Indole-3-carbinol (I3C), a
phytochemical derived from cruciferous vegetables,
decreased the metastatic spread of tumors in experimen-
tal animals in a ROCK-dependent manner [22]. In this
report, I3C stimulated the phosphorylation of cofilin by
activated ROCK, and inhibition of ROCK ablated the
I3C-induced stress fiber formation and peripheral focal
adhesion, which led to the inhibition of cell motility in
human breast cancer cells [22].
We have recently reported that Rho-kinase/ROCK
negatively regulates EGF-stimulated colon cancer cell
proliferation [23]. Moreover, we have demonstrated that
a Rho-kinase/ROCK inhibitor upregulates migration by
altering focal adhesion formation via the Akt pathway in
colon cancer cells [24], thereby indicating that ROCK
might be considered as a new therapeutic target for
colon cancer patients. However, the precise role of
ROCK in cancer cells remains to be clarified. In the pre-
sent study, we investigated the role of ROCK in the acti-
vation of the EGFR and subsequent cell proliferation
pathway in pancreatic cancer cells.
Materials and methods
Materials
The ROCK inhibitor Y27632 was obtained from Calbio-
chem-Novabiochem Co. (La Jolla, CA). EGF and TGF-a
were obtained from Sigma Chemical Co. (St. Louis,
MO) and R&D Systems (Minneapolis, MN), respectively.
Antibodies against total EGFR and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against phospho-cofilin, cofilin, phospho-myosin light
chain (MLC), phospho-EGFR (Tyr1045 and Tyr1068),
phospho-MEK1/2, MEK1/2, phospho-p44/p42 MAP
kinase, p44/p42 MAP kinase, phospho-Akt, Akt, phos-
pho-glycogen synthase kinase (GSK)-3b,G S K - 3 b and
ROCK1 were obtained from Cell Signaling, Inc. (Beverly,
MA). Anti-EGFR-neutralizing antibodies were purchased
from Millipore (Temecula, CA). The ECL Western blot
detection system was purchased from GE Healthcare
(Buckinghamshire, UK). Other materials and chemicals
were obtained from commercial sources.
Cell culture
Panc1, KP3 and AsPc1 pancreatic cancer cells were
grown in Roswell Park Memorial Institute (RPMI) 1640
(Invitrogen, San Diego, CA) medium supplemented with
10% heat-inactivated fetal calf serum (FCS), penicillin
(100 U/ml) and streptomycin (100 μg/ml) in a
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indicated, the cells were incubated in serum free med-
ium for 24 h prior to each experiment.
Cell proliferation assay
We used Cell Proliferation ELISA (BrdU) and a 3-(4,5-
dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide
(MTT) cell proliferation kit I (Roche Diagnostics Co.,
Indianapolis, IN) in accordance with instructions of the
manufacturer. In the BrdU incorporation assay, Panc1,
KP3 and AsPc1 cells were seeded onto 96-well plates (5
×1 0
3 cells/well) in RPMI containing 10% FCS, and 48 h
later, the cells were pretreated with 3 μM Y27632 or
vehicle in RPMI containing 0.3% FCS for 1 h, and then
stimulated with 30 ng/ml of EGF or vehicle for 24 h. In
the MTT assay, Panc1 cells were seeded onto 96-well
plates (3 × 10
3 cells/well), and 24 h later, the cells were
treated with the indicated doses (0, 1 and 3 μM) of
Y27632 in RPMI containing 3% FCS for 72 h. In the
EGFR blockade experiments, Panc1 cells were seeded
onto 96-well plates (1.5 × 10
3 cells/well) and 24 h later,
the cells were treated with 0.5 μg/ml of anti-EGFR-neu-
tralizing antibodies or normal mouse-IgG in RPMI con-
taining 3% FCS for 0-4 days. The medium and agents
were not changed during these periods. The remaining
cells were counted by the MTT cell proliferation kit I.
All assays were done in triplicate.
The measurement of RhoA activity
RhoA activity was measured using G-LISA™ Small G-
protein Activation Assays (Cytoskeleton, Denver, CO).
In brief, the cells stimulated with EGF (30 ng/ml) for
the indicated times were harvested using the lysis buffer
contained in the kit. The cell lysates were then analyzed
by FUJIFILM LAS-4000 multicolor (Tokyo, Japan).
Western blot analysis
The cells were lysed in lysis buffer [20 mM Tris (pH
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
TritonX-100, 2.5 mM sodium pyrophosphate, 50 mM
NaF, 50 mM HEPES, 1 mM Na3VO4 and 2 mM phenyl-
methylsulfonyl fluoride (PMSF)] and scraped from the
dishes. Protein extracts were examined by a Western
blot analysis as previously described [25]. The proteins
were fractionated and transferred onto an Immune-Blot
PVDF Membrane (Bio-Rad, Hercules, CA). The mem-
branes were blocked with 5% fat-free dry milk in phos-
phate-buffered saline (PBS) containing 0.1% Tween-20
(PBS-T) for 30 min before incubation with the indicated
primary antibodies. Peroxidase-labeled antibodies raised
in goats against rabbit IgG were used as secondary anti-
bodies. The peroxidase activity on the membrane was
v i s u a l i z e do nX - r a yf i l mb ym e a n so ft h eE C LW e s t e r n
blot detection system.
siRNA protocol
We used two types of negative controls provided by Life
Technologies (Japan; Silencer
® Negative Control #1 and
#2 siRNA). Predesigned siRNAs targeting ROCK1 (ON-
TARGET, J-003536-06, J-003536-07) were obtained
from Thermo Scientific Inc. (Waltham, MA). The
sequences were as follows; UAGCAAUCGUAGAUA-
CUUA (J-003536-07, simplified as #1) and CUACAA-
GUGUUGCUAGUUU (J-003536-06, simplified as #2).
Transfection was performed according to the manufac-
turer’s protocol (Bio-Rad, Tokyo, Japan). In brief, 5 μlo f
siLentFect (Bio-Rad) and 10 nM of siRNA were diluted
with FCS-free Opti-MEM, pre-incubated at room tem-
perature for 20 min, and then added to Opti-MEM
without FCS. The cells were incubated at 37°C for 24 h
with siRNA-siLentFect complexes, and the medium was
changed to fresh medium with 10% FCS, and cells were
incubated for an additional 24 h. They were then treated
as indicated, and subsequently harvested for the Wes-
tern blot analysis.
Immunofluorescence microscopy studies
Immunofluorescence microscopy studies were per-
formed as described previously [26]. In the ROCK inhi-
bition experiments using Y27632, the cells grown on
coverslip-bottom dishes were treated with 3 μM Y27632
or vehicle for 1 h at 37°C, followed by exposure to 30
ng/ml of EGF for 10 min at 37°C. They were then fixed
with 4% paraformaldehyde for 10 min on ice and then
exposed to 0.1% Triton X-100 for 10 min to permeabi-
lize the cell membrane. Next, they were exposed to anti-
MLC antibodies, followed by exposure to Alexa Fluor
488
®-conjugated goat anti-rabbit IgG antibodies and
4’,6-diamidino-2-phenylindole (DAPI; Wako, Tokyo,
Japan) for 1 h. In the EGFR-localization experiments,
the cells were treated with 3 μM Y27632 or vehicle for
1 h at 37°C, and then labeled for 15 min at 37°C with
anti-EGFR antibodies which recognize the extracellular
domain of the EGFR. They were then exposed to 30 ng/
ml of EGF for 10 min at 37°C. To observe only the cell
surface EGFR that remained on the plasma membrane,
these cells were not permeabilized. They were fixed and
exposed to Alexa Fluor 488
®-conjugated donkey anti-
goat IgG antibodies and DAPI for 1 h, and then exam-
ined by fluorescence microscopy using a BIOREVO sys-
tem (BZ-9000; Keyence, Tokyo, Japan) according to the
manufacturer’s protocol.
Image analysis
The protein band intensities in the Western blot analy-
sis were determined by integrating the optical density
over the band area (band volume) using the NIH image
software program. Based on the intensity of the control
protein band on the X-ray film, the protein samples
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of the cell surface EGFR-labeled Alexa 488 was also
measured and quantified using this software program.
Results
Effects of Y27632 on cell proliferation in Panc1, KP3 and
AsPc1 pancreatic cancer cells
In order to examine whether or not EGF and ROCK are
involved in pancreatic cancer cell proliferation, we first
evaluated BrdU incorporation in Panc1, KP3 and AsPc1
cells utilizing Y27632 as a specific ROCK inhibitor.
When these cells were treated with EGF (Figure 1A,
lane 2, respectively), the BrdU incorporation was
increased. Interestingly, BrdU incorporation was also
increased when these cells were treated with Y27632
alone (Figure 1A, lane 3 compared to lane 1, respec-
tively). In addition, the BrdU incorporation induced by
EGF was further enhanced when these cells were pre-
treated with Y27632 (Figure 1A, lane 4 compared to
lane 2, respectively). To verify these results, we also per-
formed another experiment using the MTT assay. The
growth of Panc1 cells was significantly enhanced when
the cells were pretreated with Y27632 at a dose over 1
μM (Figure 1B). Taken together, these results indicate
that ROCK plays a suppressive role in pancreatic cancer
cell proliferation.
Effects of anti-EGFR-neutralizing antibodies on Panc1
pancreatic cancer cell proliferation
We next examined the effect of the blockade of EGF sti-
mulation on the proliferation of Panc1 cells grown in
medium containing 3% FCS. When the cells were trea-
ted with anti-EGFR-neutralizing antibodies for 4 days,
the cell growth was significantly suppressed, compared
to the cells treated with normal IgG (Figure 1C). Since
medium containing 3% FCS is recognized to contain
various types of growth factors, including EGF, it is
likely that EGF stimulation plays an important role in
Panc1 cell proliferation. These results led us to further
investigate the role of ROCK in EGF-treated pancreatic
cancer cells.
Effects of EGF on RhoA activity and the phosphorylation
of cofilin, MLC, and the EGFR at tyrosine residues in
Panc1 cells
It is well known that EGF activates RhoA in many cell
systems [27]. In order to elucidate the involvement of
EGF in ROCK activation in Panc1 cells, we first exam-
ined the effect of EGF on RhoA activity in Panc1 cells.
As shown in Figure 2A, 30 ng/ml of EGF significantly
activated RhoA. The maximum effect was observed
within 3 min and it continued for up to 10 min, and
then decreased thereafter. These results suggest that
EGF stimulation affects ROCK through RhoA.
It is generally recognized that cofilin is one of down-
stream substrates of ROCK, indicating that phosphoryla-
tion of cofilin reflects the activation of ROCK [14].
Moreover, EGF markedly induced the phosphorylation
of cofilin in a time-dependent manner (Figure 2B). The
effect of EGF on the phosphorylation of cofilin appeared
at 5 min, reached a maximum at 10-20 min, and
decreased at 180 min after EGF-treatment (Figure 2B,
first panel). EGF also markedly and immediately induced
the phosphorylation of EGFR at Tyr1045 and Tyr1068
at 0.5 min, reached a maximum within 1 min (data not
shown), continued for up to 60 min, and decreased at
120 min after EGF-treatment (Figure 2B, 3rd and 4th
panels). These results indicate that the activation of
EGFR induced by EGF preceded the phosphorylation of
Figure 1 The effects of Y27632 and EGF on pancreatic cancer
cell proliferation. (A) Panc1, KP3 and AsPc1 cells were pretreated
with 3 μM Y27632 or vehicle in RPMI containing 0.3% FCS for 1 h,
and then stimulated with 30 ng/ml of EGF or vehicle for 24 h. The
BrdU incorporation as the % of the control (lane 1) is shown. (B)
Panc1 cells were treated with the indicated doses of Y27632 or
vehicle in RPMI containing 3% FCS for 48 h, and the cell viability
assay was performed using the MTT cell proliferation kit I. (C) The
attached cells were treated with 0.5 μg/ml of normal mouse-IgG
(open circle) or anti-EGFR-neutralizing antibodies (closed circle) for
the indicated periods in medium containing 3% FCS, and the
surviving cells were counted using the MTT cell proliferation kit I.
The results are expressed as the absorbance (OD 560 nm-OD 750
nm). All assays were done in triplicate. (*) indicates a significant
difference (p < 0.05) compared with lane 1, (#) indicates a
significant difference (p < 0.05), compared with lane 2.
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cells.
We next examined whether Y27632 inhibits the EGF-
induced phosphorylation of cofilin. We observed that
EGF induced the phosphorylation of cofilin (Figure 2C;
upper panel, lane 2 compared to lane 1), and 3 μMo f
Y27632 completely suppressed the EGF-induced phos-
phorylation of cofilin (Figure 2C; upper panel, lane 4
compared to lane 2). Interestingly, Y27632 alone did not
suppress the phosphorylation of cofilin at the basal level
(Figure 2C; upper panel, lane 3 compared to lane 1).
The phosphorylation of MLC plays a critical role in
controlling actomyosin contractility in smooth muscle
and non-muscle cells [28], and ROCK has been reported
to directly phosphorylate MLC in vitro [29]. To confirm
that EGF activates ROCK in Panc1 cells, we examined
the effects of EGF on the phosphorylation of MLC in an
immunofluorescence microscope study. When the cells
were stimulated with 30 ng/ml of EGF for 10 min, phos-
phorylated MLC was clearly observed in the cells (Fig-
ure 2D, panel 2 compared to panel 1). Moreover,
pretreatment with 3 μM Y27632 markedly reduced the
EGF-induced MLC phosphorylation (Figure 2D, panel 4
compared to panel 2). Taken together, these data
strongly suggest that EGF induces the activation of
ROCK via RhoA, and that the phosphorylation of cofilin
and MLC by EGF occurs through ROCK in Panc1 pan-
creatic cancer cells.
Effects of Y27632 on the phosphorylation of EGFR at
tyrosine residues in Panc1, KP3 and AsPc1 pancreatic
cancer cells
The EGFR is a transmembrane glycoprotein with an
extracellular ligand-binding domain [30]. Binding of spe-
cific ligands such as EGF and TGF-a to the extracellular
domain results in EGFR dimerization and autopho-
sphorylation of the tyrosine kinase domain, leading to
the activation of downstream signaling pathways that
are involved in cell proliferation and survival [31]. We
next examined the effects of Y27632 on the EGF-
induced phosphorylation of EGFR at Tyr1045 and
Tyr1068 in Panc1, KP3 and AsPc1 cells. Pretreatment of
the cells with Y27632 for 1 h caused a significant
increase in the phosphorylation levels of EGFR at
Tyr1045 and Tyr1068 (Figure 3A, B and 3C). We also
examined the effects of Y27632 on the TGF-a-induced
phosphorylation of EGFR at Tyr1045 and Tyr1068 in
Panc1 and KP3 cells, and obtained similar results to
those obtained using EGF (Figures 3A and 3B; lower
panels, respectively).
There are two isoforms of ROCK, known as ROCK1
and ROCK2, that share 65% overall homology at the
amino acid level [32]. The tissue distribution of
ROCK1 and ROCK2 is similar, and relatively few
Figure 2 The effects of EGF on RhoA activity and the
phosphorylation of cofilin, MLC and EGFR at tyrosine residues
in Panc1 cells. (A) Panc1 cells were stimulated with 30 ng/ml of
EGF for the indicated periods, and RhoA activity was measured by
G-LISA™ Small G-protein Activation Assays. The results are
expressed as the fold increase compared with untreated control
cells. Bars designate SD of triplicate assays. (*) indicate significant
increases (p < 0.05) compared to control cells. (B) Panc1 cells were
stimulated with 30 ng/ml of EGF for the indicated periods. (C)
Panc1 cells were pretreated with 3 μM Y27632 or vehicle for 1 h,
and stimulated with 30 ng/ml of EGF or vehicle for 10 min. The cell
lysates were then harvested and Western blotting were performed
with antibodies against phospho-cofilin, cofilin, phospho-EGFR
(Tyr1045 and Tyr1068), EGFR and GAPDH. The intensities of protein
bands were determined by integrating the optical density over the
band area using the NIH image software program. The intensity of
each protein band was divided by the control (lane 1), and is
shown above each panel. (D) Panc1 cells were treated with 3 μM
Y27632 or vehicle for 1 h, followed by exposure to 30 ng/ml of EGF
or vehicle for 10 min. After fixation, they were exposed to anti-
phospho MLC antibodies, Alexa Fluor 488
®-conjugated goat anti-
rabbit IgG antibodies and DAPI. The cells were examined by
fluorescence microscopy.
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ROCK [33]. To further verify that the inhibition of
ROCK enhances EGF-induced phosphorylation of
EGFR at tyrosine residues, we performed siRNA
experiments, in which we transfected into Panc1 cells
with negative control (NC)-siRNA or siRNA specifi-
cally targeting ROCK1. We verified that 10 nM of the
siRNAs specifically targeting ROCK1 (both #1 and #2)
caused 70% protein knockdown whereas 10 nM of the
NC-siRNA did not affect the protein level of ROCK1
(Figure 3D; upper panels). We also confirmed this
using another NC-siRNA (see Materials and Methods;
data not shown). As expected, knockdown of ROCK1
caused significant enhancement of the phosphorylation
levels of the EGFR at tyrosine residues (Figure 3D;
lower panels), which is consistent with our results
s h o w ni nF i g u r e s3 A - C .
Effects of Y27632 on the EGF-induced phosphorylation of
MEK1/2, p44/p42 MAP kinase, Akt and GSK-3b in Panc1
pancreatic cancer cells
Two of the better-understood EGFR signal transduction
pathways involved in cell proliferation are the Ras-Raf-
MEK-p44/p42 MAP kinase pathway and the PI3K/Akt
pathway [7]. Since pretreatment with Y27632 enhanced
t h ep h o s p h o r y l a t i o no ft h eE G F Ra tt y r o s i n er e s i d u e s
(Figures 3A, B and 3C), we next examined the effects of
Y27632 on the EGF-induced phosphorylation of MEK1/
2a n dp 4 4 / p 4 2M A Pk i n a s ei nP a n c 1c e l l s .T h ee f f e c t s
of EGF on the phosphorylation of MEK1/2 and p44/p42
MAP kinase started at 1 min (data not shown), reached
a maximum within 5 min, and decreased thereafter (Fig-
ure 4A, lanes 1-6). As expected, the EGF-induced
MEK1/2 and p44/p42 MAP kinase phosphorylation
were markedly increased and prolonged when the cells
Figure 3 The effects of Y27632 or ROCK1-siRNA on either EGF or TGF-a-induced phosphorylation of EGFR at tyrosine residues.( A - C )
Panc1 (A), KP3 (B) and AsPc1 (C) cells were pretreated with the indicated concentrations of Y27632 or vehicle for 1 h, and then stimulated with
30 ng/ml of EGF or 30 ng/ml of TGF-a or vehicle for 5 min. The cell lysates were then harvested and Western blotting were performed with
antibodies against phospho-EGFR (Tyr1045 and Tyr1068), EGFR and GAPDH. (D) Upper panels; Panc1 cells were transfected with 10 nM of a
negative control siRNA or siRNAs specifically targeting ROCK1 (#1 and #2) for 48 h, and then stimulated with 30 ng/ml of EGF or vehicle for 5
min. The cell lysates were then harvested and Western blotting was performed with antibodies against ROCK1, phospho- EGFR (Tyr1068), EGFR
and GAPDH. The intensities of protein bands in the Western blot analysis were determined by integrating the optical density over the band area
using the NIH image software program. The intensity of each protein band was divided by the control (lane 1), and is shown above each panel.
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Panc1 cells. (A) The cells were pretreated with 3 μM Y27632 or vehicle for 1 h, and then stimulated with 30 ng/ml of EGF or vehicle for the
indicated periods. (B) The cells were transfected with 10 nM of a negative control siRNA or siRNAs specifically targeting ROCK1 (#1) for 48 h, and
then stimulated with 30 ng/ml of EGF or vehicle for 5 min. The cell lysates were then harvested and Western blotting were performed with
antibodies against phospho-MEK1/2, MEK1/2, phospho-p44/p42 MAP kinase, p44/p42 MAP kinase, phospho-Akt, Akt, phospho-GSK-3b, GSK-3b
and GAPDH. The intensities of protein bands in the Western blot analysis were determined by integrating the optical density over the band area
using the NIH image software program. The intensity of each protein band was divided by the control (lane 1), and is shown above each panel.
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4A, lanes 7-12 compared to lanes 1-6).
We next examined the effects of Y27632 on the
EGF-induced phosphorylation of Akt and GSK-3b in
Panc1 cells, since GSK-3b is a critical downstream
element of the PI3K/Akt pathway in EGFR signaling
[34]. The effects of EGF on the phosphorylation of
Akt and GSK-3b also reached a maximum within 5
min and decreased thereafter (Figure 4A, lanes 1-6).
The EGF-induced phosphorylation of Akt and GSK-
3b were also significantly enhanced when the cells
were pretreated with 3 μM Y27632 for 1 h, although
the increases were less dramatic than those for either
MEK1/2 or p44/p42 MAP kinase. These findings
agree with our results showing that pretreatment
with Y27632 enhanced the phosphorylation of the
EGFR at tyrosine residues (shown in Figure 3).
Furthermore, knockdown of ROCK1 caused a signifi-
cant enhancement of the phosphorylation levels of
MEK1/2, p44/p42, Akt and GSK-3b (Figure 4B),
which was also consistent with our results shown in
Figure 4A.
Effects of Y27632 on the internalization of the EGFR in
Panc1 pancreatic cancer cells
It is well known that EGF induces the internalization of
the EGFR, and this is associated with subsequent ubi-
quitin-mediated degradation of the EGFR [35]. We
showed in Figures 3 and 4 that Y27632 remarkably pro-
longed the EGF-induced activation of EGFR and subse-
quent signaling via MEK1/2 and Akt. Therefore, we
next examined whether Y27632 affects the EGFR inter-
nalization by performing an immunofluorescence micro-
scope study. In this assay, the cells were not
permeabilized using Triton X-100 in order to observe
the remaining EGFR on the cell surface. In unstimulated
Panc1 cells, antibody-tagged EGFR was observed on the
cell membrane (Figure 5A, panel 1), and the cell surface
EGFR was significantly decreased when the cells were
treated with EGF (Figure 5A, panel 2), which is consis-
tent with our previous study [36]. Interestingly, when
the cells were pretreated with increasing doses of
Y27632, antibody-tagged EGFR still remained on the
cells surface even after EGF stimulation for 10 min (Fig-
ure 5A, panels 4 and 6), while Y27632 alone had no
effect on the localization of the EGFR (Figure 6A, panels
3 and 5). Quantification of the green fluorescence inten-
sities of cell surface EGFR labeled with Alexa 488
revealed that the EGF-induced decrease in cell surface
EGFR was restored by pretreatment with Y27632 in a
dose-dependent manner (Figure 5B). These results
strongly suggest that the inhibition of ROCK delayed
the internalization of the EGFR induced by EGF in
Panc1 cells.
Discussion
I nt h ep r e s e n ts t u d y ,w ei n v e s t i g a t e dt h er o l eo fR O C K
in the proliferation of pancreatic cancer cells. We
showed that Y27632, a specific ROCK inhibitor,
enhanced cell proliferation (Figure 1A and 1B), thus
suggesting a suppressive role of ROCK in pancreatic
cancer cell proliferation. In addition, we found that
EGF stimulation was necessary for cell growth in an
experiment utilizing anti-EGFR-neutralizing antibodies
to block EGFR signaling (Figure 1C). Therefore, we
performed subsequent experiments focusing on the
relationship between ROCK and EGF signaling. We
demonstrated that EGF induced RhoA activity (Figure
Figure 5 The effects of Y27632 on the internalization of the
EGFR in Panc1 pancreatic cancer cells. (A) Panc1 cells were
treated with the indicated concentrations of Y27632 or vehicle for 1
h at 37°C, and then labeled for 15 min at 37°C with anti-EGFR
antibodies which recognize the extracellular domain of the EGFR.
The cells were then exposed to 30 ng/ml of EGF for 10 min at 37°C.
To observe only the cell surface EGFR that remained on the plasma
membrane, these cells were not permeabilized with Triton X-100.
They were then exposed to Alexa Fluor 488
®-conjugated donkey
anti-goat IgG antibodies and DAPI for 1 h. Representative cells
examined by fluorescence microscopy are shown. (B) Green
fluorescence signals from the remaining cell surface EGFR were
measured using the NIH image software program, and expressed as
the % of the control (compared with untreated control cells).
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MLC (Figure 2B), known downstream targets of ROCK
[14]. We also demonstrated that Y27632 suppressed
the phosphorylation of both molecules (Figure 2C and
2D), thus suggesting that the phosphorylation of cofilin
and MLC by EGF occurs through ROCK in pancreatic
cancer cells. We also found that the phosphorylation
of the EGFR induced by EGF preceded the activation
of ROCK (Figure 2B). Based on our findings, it is pos-
sible that the ROCK activation induced by EGF plays
an inhibitory role in cell proliferation.
We next investigated the correlation between ROCK
and EGF signaling, and found that exposure to Y27632
or knockdown of ROCK using siRNA strengthened the
EGF-induced phosphorylation of EGFR at Tyr1045 and
Tyr1068 (Figure 3). Moreover, the inhibition of ROCK
activation using Y27632 or siRNA significantly augmen-
ted and prolonged the EGF-induced activation of
MEK1/2 and p44/p42 MAP kinase, as well as Akt and
GSK-3b (Figure 4). Taken together, our findings suggest
that ROCK negatively regulates the EGFR pathway in
pancreatic cancer cells. Moreover, Y27632 retarded the
internalization of the EGFR induced by EGF (Figure 6),
suggesting that ROCK is involved in the trafficking of
the EGFR. While it has previously been reported that
cell surface EGFR promotes cell growth, and that inter-
nalization of the EGFR induces cell death in breast can-
cer cells [37], our present findings suggest that cell
surface EGFR retained after Y27632 treatment exerts
pro-proliferative signals.
Our hypothetical pathway underlying ROCK-mediated
signaling is summarized in Figure 6. After EGF binds to
EGFR molecules on the cell surface, the receptor under-
goes dimerization and autophosphorylation at tyrosine
residues. This triggers EGFR-related downstream signal-
ing, such as through the MEK1/2-p44/p42 MAP kinase
or Akt pathways, within 5 min of stimulation (Figure 4).
Around 5 min after stimulation is initiated, EGF starts
to induce RhoA-mediated activation of ROCK, as
demonstrated by up-regulation of cofilin and MLC
phosphorylation (Figure 2). Inhibition experiments with
Y27632 or siRNA indicated that ROCK suppresses the
activation of the EGFR and the downstream pathways of
MEK1/2 and Akt beginning at 5 min after the start of
stimulation (Figures 3 and 4).
In addition to the elevated expression of RhoA,
increased levels of ROCK have been reported to be
observed in esophageal squamous cell carcinoma [38],
bladder cancer [39] and pancreatic cancer [21]. In this
study, the inhibition of ROCK prolonged EGFR signal-
ing by preventing EGFR internalization, thus suggesting
that ROCK functions to switch off the EGFR signaling
by promoting EGFR desensitization. We speculate that
the following occurs; 1) rapid growth of cancer cells
results in overexpression ofR O C K ;2 )d y s f u n c t i o no f
ROCK in cancer cells; 3) ROCK does not function in
normal pancreatic cells, because they lack EGFR
expression.
In addition, we transfected Panc1 cells with a ROCK1-
encoding and examined the effect of EGF on EGFR
phosphorylation in these cells. However, we did not
observe any changes in the phosphorylation status of
the EGFR induced by EGF between ROCK1-overexpres-
sing cells and control cells (data not shown). This might
be due to the fact that ROCK1 expression is already
Figure 6 A schematic representation of the involvement of
ROCK in the EGFR signaling in pancreatic cancer cells. First, EGF
binds to the EGFR on the cell surface, and the EGFR undergoes
dimerization and autophosphorylation at tyrosine residues. This
triggers EGFR-related downstream signaling, such as activation of
the MEK1/2-p44/p42 MAPK or Akt pathways, within 5 min of EGF
stimulation (①). Around 5 min after the start of stimulation, EGF
starts to induce the activation of RhoA and subsequently ROCK, as
demonstrated by upregulation of the phosphorylation of cofilin and
MLC (②). Inhibition experiments using Y27632 or siRNA indicated
that activated ROCK cancels the persistent activation of the EGFR
and the downstream pathways of MEK1/2 and Akt beginning at 5
min after the initiation of stimulation. Thus, ROCK functions to
switch off the EGFR signaling that induces pancreatic cancer cell
proliferation. EGF: epidermal growth factor, EGFR: EGF receptor,
ROCK: Rho-associated coiled-coil containing protein kinase, MAPK:
mitogen-activated protein kinase, GSK-3b: glycogen synthase kinase-
3b, MLC, myosin light chain, P: phosphorylation, Y: tyrosine.
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Page 9 of 11abundant in pancreatic cancer cells (Figure 3D). Taking
all of this information into account, we speculate that
ROCK1 is likely to be overexpressed in tumor tissues,
and that it controls tumor invasion by a negative feed-
back system, because of the presence of excessive EGFR
stimulation and the subsequent ROCK response in can-
cer cells. Moreover, we recently showed that ROCK sup-
pressed Akt-dependent cell migration in colon cancer
cells, thus suggesting that ROCK is also involved in
metastatic events [24] in addition to cell proliferation.
With regard to the translation of this information to
the clinic, appropriate regulation of ROCK might have
the potential to be used as a new therapeutic target for
human cancer, including pancreatic cancer, although
further investigations are required to elucidate the exact
mechanism(s) underlying how ROCK negatively regu-
lates the activation of the EGFR.
Conclusions
While EGF first stimulates the activation of EGFR, and
subsequently induces pancreatic cancer cell prolifera-
tion, concurrent EGF-induced the activation of ROCK
then turns off the activated EGFR pathway.
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